Pfizer Aktie
WKN: 852009 / ISIN: US7170811035
25.02.2025 02:27:45
|
Akeso's Partner Summit, Pfizer Collaborate To Evaluate Ivonescimab In Solid Tumor Settings
(RTTNews) - Akeso Inc. has announced that Summit Therapeutics Inc. (SMMT), its partner for ivonescimab, has entered into a clinical trial collaboration with Pfizer Inc. (PFE). This collaboration aims to evaluate ivonescimab, a novel investigational PD-1/VEGF bispecific antibody, in combination with several of Pfizer's antibody drug conjugates (ADCs) across multiple solid tumor settings.
The collaboration's goal is to accelerate the advancement of potentially groundbreaking combinations that could enhance the standards of care for patients with serious unmet needs. Each study will assess ivonescimab in combination with one of Pfizer's vedotin ADCs in distinct solid tumor settings, focusing on determining the safety profile and potential anti-tumor activity of these combinations.
As per the terms of the agreement, Summit will supply ivonescimab for the proposed studies, while Pfizer will handle the study operations. Both Summit and Pfizer will oversee the studies and retain their respective rights to their products. The studies involving ivonescimab and Pfizer's vedotin ADCs are expected to commence in the middle of this year. Summit will provide further details on the clinical trials at a later date.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Pfizer Inc.mehr Nachrichten
20.10.25 |
ANALYSE-FLASH: JPMorgan belässt Pfizer auf 'Neutral' - Ziel 30 Dollar (dpa-AFX) | |
14.10.25 |
Novo Nordisk-Aktie im Minus: Gelingt auch hier ein US-Deal wie bei Pfizer und AstraZeneca? (finanzen.at) | |
14.10.25 |
S&P 500-Papier Pfizer-Aktie: So viel Verlust hätte ein Investment in Pfizer von vor 5 Jahren eingebracht (finanzen.at) | |
13.10.25 |
AstraZeneca-Aktie im Minus: Zollnachlässe für Preissenkungen - AstraZeneca folgt Pfizer-Beispiel in den USA (dpa-AFX) | |
07.10.25 |
S&P 500-Papier Pfizer-Aktie: So viel hätte eine Investition in Pfizer von vor 3 Jahren gekostet (finanzen.at) | |
01.10.25 |
Pfizer-Deal beflügelt Pharmaaktien: Merck, Bayer, Novo Nordisk, J&J & Co. im Plus (dpa-AFX) | |
01.10.25 |
AKTIEN IM FOKUS 2: US-Deal mit Pfizer hilft gesamter Pharmabranche (dpa-AFX) | |
30.09.25 |
Pluszeichen in New York: S&P 500 schlussendlich fester (finanzen.at) |
Analysen zu Pfizer Inc.mehr Analysen
20.10.25 | Pfizer Neutral | JP Morgan Chase & Co. | |
02.10.25 | Pfizer Buy | Jefferies & Company Inc. | |
01.10.25 | Pfizer Buy | Jefferies & Company Inc. | |
30.09.25 | Pfizer Neutral | JP Morgan Chase & Co. | |
24.09.25 | Pfizer Buy | Jefferies & Company Inc. |
Aktien in diesem Artikel
Pfizer Inc. | 21,44 | 1,13% |
|